Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1974 1
1975 5
1976 2
1977 1
1978 4
1979 2
1980 1
1981 3
1982 5
1983 7
1984 1
1985 3
1986 4
1987 7
1988 7
1989 4
1990 9
1991 10
1992 10
1993 7
1994 13
1995 9
1996 13
1997 11
1998 14
1999 16
2000 17
2001 17
2002 17
2003 24
2004 16
2005 24
2006 14
2007 17
2008 17
2009 21
2010 21
2011 13
2012 24
2013 35
2014 50
2015 51
2016 60
2017 67
2018 61
2019 69
2020 91
2021 111
2022 85
2023 73
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,070 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. Zinzani PL, et al. J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28. J Clin Oncol. 2023. PMID: 37506346 Clinical Trial.
ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL). METHODS: Patients with R/R FL who had received 2 lines of therapy, including a …
ROSEWOOD is a phase II, randomized study that assessed the efficacy and safety of ZO versus obinutuzumab in patients with relapsed/refractor …
Reviews.
[No authors listed] [No authors listed] New Phytol. 1991 Mar;117(3):507-514. doi: 10.1111/j.1469-8137.1991.tb00015.x. New Phytol. 1991. PMID: 33874310 Free article. Review.
By C. L. Campbell and L. V. Madden British Woodland Produce By J. R. Aaron and E. G. Richards The Structural Biology of Palms. By P. B. Tomlinson The Carnivorous Plants. By B. E. Juniper, R. J. Robins and D. M. joel The Evolution and Classification of …
By C. L. Campbell and L. V. Madden British Woodland Produce By J. R. Aaron and E. G. Richards The Structural Biology of Palms. …
Erratum for the Research Article: "Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance" by J. M. Giltnane, K. E. Hutchinson, T. P. Stricker, L. Formisano, C. D. Young, M. V. Estrada, M. J. Nixon, L. Du, V. Sanchez, P. G. Ericsson, M. G. Kuba, M. E. Sanders, X. J. Mu, E. M. Van Allen, N. Wagle, I. A. Mayer, V. Abramson, H. Gmez, M. Rizzo, W. Toy, S. Chandarlapaty, E. L. Mayer, J. Christiansen, D. Murphy, K. Fitzgerald, K. Wang, J. S. Ross, V. A. Miller, P. J. Stephens, R. Yelensky, L. Garraway, Y. Shyr, I. Meszoely, J. M. Balko, C. L. Arteaga.
[No authors listed] [No authors listed] Sci Transl Med. 2019 Feb 13;11(479):eaaw7620. doi: 10.1126/scitranslmed.aaw7620. Sci Transl Med. 2019. PMID: 30760583 No abstract available.
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study.
Yaghi S, Shu L, Mandel D, Leon Guerrero CR, Henninger N, Muppa J, Affan M, Ul Haq Lodhi O, Heldner MR, Antonenko K, Seiffge D, Arnold M, Salehi Omran S, Crandall R, Lester E, Lopez Mena D, Arauz A, Nehme A, Boulanger M, Touze E, Sousa JA, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito MT, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann JE, Engelter ST, Traenka C, Aguiar de Sousa D, Soares M, Rosa S, Zhou LW, Gandhi P, Field TS, Mancini S, Metanis I, Leker RR, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte CH, Choi R, MacDonald J, Bavarsad Shahripour R, Guo X, Ghannam M, Almajali M, Samaniego EA, Sanchez S, Rioux B, Zine-Eddine F, Poppe A, Fonseca AC, Baptista MF, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind DS, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy-Rivas R, Aziz Y, Bakradze E, Tran TL, Rodrigo-Gisbert M, Requena M, Saleh Velez F, Ortiz Gracia J, Mudassani V, de Havenon A, Vishnu VY, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Sieg… See abstract for full author list ➔ Yaghi S, et al. Stroke. 2024 Apr;55(4):908-918. doi: 10.1161/STROKEAHA.123.045731. Epub 2024 Feb 9. Stroke. 2024. PMID: 38335240 Free article.
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, Jagt RV, Janssens A, Kneba M, Mayer J, Young M, Schmidt C, Knapp A, Nielsen T, Brown H, Spielewoy N, Harbron C, Bottos A, Mundt K, Marcus R, Hiddemann W, Hoster E. Pott C, et al. J Clin Oncol. 2024 Feb 10;42(5):550-561. doi: 10.1200/JCO.23.00838. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096461 Clinical Trial.
G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. During the maintenance period, more patients treated with R than with G were MRD-positive (R-CHOP, 20.7% v G-CHOP, 7.0%; R-C …
G appeared to compensate for less effective chemotherapy regimens, with similar MRD response rates observed across the G-chemo groups. Durin …
Rare variant enrichment analysis supports GREB1L as a contributory driver gene in the etiology of Mayer-Rokitansky-Kuster-Hauser syndrome.
Jolly A, Du H, Borel C, Chen N, Zhao S, Grochowski CM, Duan R, Fatih JM, Dawood M, Salvi S, Jhangiani SN, Muzny DM, Koch A, Rouskas K, Glentis S, Deligeoroglou E, Bacopoulou F, Wise CA, Dietrich JE, Van den Veyver IB, Dimas AS, Brucker S, Sutton VR, Gibbs RA, Antonarakis SE, Wu N, Coban-Akdemir ZH, Zhu L, Posey JE, Lupski JR. Jolly A, et al. HGG Adv. 2023 Mar 29;4(3):100188. doi: 10.1016/j.xhgg.2023.100188. eCollection 2023 Jul 13. HGG Adv. 2023. PMID: 37124138 Free PMC article.
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is characterized by aplasia of the female reproductive tract; the syndrome can include renal anomalies, absence or dysgenesis, and skeletal anomalies. ...
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is characterized by aplasia of the female reproductive tract; the syndrome can include …
Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea).
Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, Razquin C, Zheng Y, Ruiz-Canela M, Guasch-Ferré M, Corella D, Gómez-Gracia E, Fiol M, Estruch R, Ros E, Lapetra J, Fito M, Aros F, Serra-Majem L, Lee CH, Clish CB, Liang L, Salas-Salvadó J, Martínez-González MA, Hu FB. Wang DD, et al. Circulation. 2017 May 23;135(21):2028-2040. doi: 10.1161/CIRCULATIONAHA.116.024261. Epub 2017 Mar 9. Circulation. 2017. PMID: 28280233 Free PMC article. Clinical Trial.
Biobanking for better healthcare.
Riegman PH, Morente MM, Betsou F, de Blasio P, Geary P; Marble Arch International Working Group on Biobanking for Biomedical Research. Riegman PH, et al. Mol Oncol. 2008 Oct;2(3):213-22. doi: 10.1016/j.molonc.2008.07.004. Epub 2008 Jul 30. Mol Oncol. 2008. PMID: 19383342 Free PMC article. Review.
An easier access to these samples for the scientific community is considered as the main bottleneck for research for health, and biobanks are the most adequate site to try to resolve this issue [Ozols, R.F., Herbst, R.S., Colson, Y.L., Gralow, J., Bonner, …
An easier access to these samples for the scientific community is considered as the main bottleneck for research for health, and biobanks ar …
ICOPLAST-from infancy to the First World Congress.
Evans GRD, Murphy RX, Rakhorst HA, Lessard L, Khashaba A, Kirschbaum JD, Mayer HF. Evans GRD, et al. Eur J Plast Surg. 2022;45(2):365-370. doi: 10.1007/s00238-022-01947-0. Epub 2022 Apr 5. Eur J Plast Surg. 2022. PMID: 35400848 Free PMC article. No abstract available.
1,070 results